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Abstract: 
Breast cancer is still one of the leading causes of cancer death
 
in women, but there has been a sustained 
decline in mortality
 
rates over the last decades the relationship between breast cancer and thyroid 
diseases is controversial many works have been done in past also. The relation between autoimmune 
and non-autoimmune thyroid diseases has been investigated in patients with breast cancer and age-
matched control individuals without breast or thyroid disease. Determination of serum thyroid hormone 
and antibody levels was done in 100 breast cancer patients and 75 control individuals. The mean values 
for thyroid hormones and anti-thyroid peroxidase antibodies were significantly higher in breast cancer 
patients than in control individuals. Our results indicate an increased prevalence of autoimmune and 
non-autoimmune thyroid diseases in breast cancer patients. 
Keywords: breast, cancer, autoimmune thyroid diseases. 
1. Introduction 
Breast cancer is a hormone-dependent neoplasm. It is the most common malignancy in women in 
western
 
countries and accounts for 18.4% of all cancers in female patients (Sidransky d.1991). 
Qualitative changes
 
in the lifestyle of women in developed countries that can influence
 
risk factors for 
breast cancer, such as age at menarche, menopause,
 
or first pregnancy, may partially explain this 
phenomenon (Sidransky 1992). Conflicting results regarding the clinical correlation between breast 
cancer and thyroid diseases have been reported in the literature (Mittra I., 1976 and Shering sg, 1996). 
Many studies showed that thyroid diseases are common among women with breast cancer whereas 
other reports did not confirm such an association of breast cancer with thyroid diseases (Maruchi n, 
1976, Lemmarie m, 1986, Moossa ar, 1973,  Kurland lt, 1976 and Anker gb, 1998 ). The objective of 
this study was to determine the relationship between breast cancer and autoimmune thyroid diseases 
(AITDS). Some authors have reported a higher prevalence of aitds among breast cancer patients than in 
age-matched control individuals (Gogas j, 2001, Myhil j, 1966 and Giani c, 1986). The aim of the 
present study was to determine the prevalence of thyroid diseases in patients with breast cancer as 
compared with that in the general female population. 
2. Materials and methods 
2.1 Patient selection 
Study was carried out in Sher-i-Kashmir University of Agricultural Sciences and Technology Srinagar 
in association with Govt. Medical College Srinagar. The study included 100 patients with Breast cancer 
and 75 controls (healthy volunteers). Breast cancer patients were 38–80 years old (median age 63 years) 
and were without any known thyroid disease. All patients were studied before any radio or chemo 
therapy.  
2.2 Study included the following examinations 
Serum free Tri-iodothyronine (T3) and free thyroxine (T4) levels were determined in both patients and 
controls based on a solid-phase I
125 
radioimmunoassay designed for the quantitative measurement of 
free T3 and free T4 levels in serum using coat-a-count kit containing radioactive I
125
-T3 or T4 analogue. 
Also, serum thyroid-stimulating hormone (TSH) levels were measured using a Immunoradiometric 
assay designed for Quantitative Measurement of TSH in serum using coat-a-count kit containing 
radioactive I
125
-polyclonal anti-TSH. The normal ranges were 2.2–6.8 pmol/l (1.4–4.4 pg/ml) for free 
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T3, 0.8–2.0 ng/dl for free T4 and 0.3–5.0 μIU/ml for TSH. All patients underwent serological 
determination of thyroid autoantibodies based on a direct anti-TPO radioimmunoassay kit for 
quantitative determination of anti-TPO autoantibodies (immunotech). Autoantibodies specific for 
thyroglobulin were measured using a quantitative indirect enzyme immunoassay based on the sandwich 
method (antithyroglobulin immunoradiometric assay kit; immunotech). The normal ranges were 0–60 
IU/ml for antithyroglobulin antibodies and 0–20 IU/ml for anti-TPO antibodies. Those women without 
any breast or thyroid disease were the control group.  
3. Results: 
Evaluation of thyroid function was based on serum thyroid hormones. The mean values for serum 
thyroid hormones were 7.25±0. 75 pmol/l for free t3, 2.93±0.57 ng/dl for free t4 and 4.12±1.40 μIU/ml 
for TSH in breast cancer patients, and 3.42±0.91 pmol/l, 1.39±0.21 ng/dl and 1.39±0.79 μIU/ml 
respectively in the control group. The mean values for serum thyroid autoantibodies were 
104.57±19.39- iu/ml for anti-TPO antibodies in breast cancer patients, and 24.81±5.16 IU/ml and, in 
the control group (table-1). 
Thus, the mean value for thyroid hormones and anti-TPO antibodies was higher in breast 
cancer patients than in the control group (p=0.030) and using statistical analysis it has been proposed 
that the presence of thyroid abnormalities may influence breast cancer progression.  
4. Discussion 
The coincidence of thyroid disease and breast cancer has long been a subject of debate. Geographical 
variations in the incidence of breast cancer have been attributed to differences in dietary iodine intake, 
and an effect of iodine on the breast has been postulated (Mittra I., 1976). the possible interactions 
between thyroid gland and breast tissue are based on the common property of the mammary and 
thyroid epithelial cell to concentrate iodine by a membrane active transport mechanism (Giani c, 1986) 
as well as on the presence of TSH receptors in fatty tissue, which is abundant in mammary gland 
(Davies tf. 1994). Additionally, some endocrine stimuli identified in thyroid products that exert a 
simultaneous action on the breast and the various thyroid antibodies, which could also interact with 
receptors on breast tumours, have been postulated to be responsible for the coincidence of mammary 
and thyroid gland disorders (Ron e., 1984 and Dumont je, 1991). The present study found high 
prevalence of thyroid hormones and autoimmune thyroiditis, in breast cancer patients. With the use of 
specific immunoassays for TPO and thyroglobulin antibodies, an increased level of TPO has been 
demonstrated in breast cancer. It has been proposed that the presence of thyroid abnormalities may 
influence breast cancer progression (Smyth,1988). A recent report suggested a better prognosis for 
breast cancer among patients with increased levels of TPO (Smyth,1988). It has been proposed that the 
immune response might be directed both by tumour and by thyroid tissue, (Smyth ppa, 2000), or that 
the tumour and thyroid tissue share common properties, as they both express TPO and the sodium 
iodide symporter gene (Spitzweg c,1998 and Kilbane mtta, 1998), 
5. Conclusion  
In this paper, we have studied thyroid autoantibody levels and thyroid function tests in breast cancer 
patients and controls. Abnormal thyroid gland characteristics were revealed in the breast cancer 
patients compared with the control group. There was a significant difference between the groups in 
terms of TPo antibody levels. These results indicate a significant association between breast cancer and 
thyroid disorders 
6. Abbreviations 
T3 = triiodothyronine; AITD = autoimmune thyroid disease; ER = Estrogen receptor; T4 = Thyroxine; 
TSH = Thyroid-Stimulating Hormone; TPO = Thyroid Peroxidase. 
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Table 1 
Serum thyroid hormone and antibody levels 
 
 Patients  Control P  
Free t3 (pmol/l) 7.25±0. 75 3.42±0.91 0.48 
 
Free t4 (ng/dl)  2.93±0.57 1.39±0.21 0.51 
 
Tsh (μIU/ml 4.12±1.40  1.39±0.79 0.27 
 
Anti-TPO antibodies (iu/ml)  104.57±19.39 24.81±5.16 0.030 
 
 
T3, triiodothyronine; T4, thyroxine; TPO, thyroid peroxidase; TSH , thyroid-stimulating hormone. 
This academic article was published by The International Institute for Science, 
Technology and Education (IISTE).  The IISTE is a pioneer in the Open Access 
Publishing service based in the U.S. and Europe.  The aim of the institute is 
Accelerating Global Knowledge Sharing. 
 
More information about the publisher can be found in the IISTE’s homepage:  
http://www.iiste.org 
 
The IISTE is currently hosting more than 30 peer-reviewed academic journals and 
collaborating with academic institutions around the world.   Prospective authors of 
IISTE journals can find the submission instruction on the following page: 
http://www.iiste.org/Journals/ 
The IISTE editorial team promises to the review and publish all the qualified 
submissions in a fast manner. All the journals articles are available online to the 
readers all over the world without financial, legal, or technical barriers other than 
those inseparable from gaining access to the internet itself. Printed version of the 
journals is also available upon request of readers and authors.  
IISTE Knowledge Sharing Partners 
EBSCO, Index Copernicus, Ulrich's Periodicals Directory, JournalTOCS, PKP Open 
Archives Harvester, Bielefeld Academic Search Engine, Elektronische 
Zeitschriftenbibliothek EZB, Open J-Gate, OCLC WorldCat, Universe Digtial 
Library , NewJour, Google Scholar 
 
 
